Description of Innate Pharma Sa's Business Segments
Innate Pharma SA is a prominent biopharmaceutical company dedicated to the advancement of innovative treatments for various health challenges, specifically focusing on oncology and inflammatory diseases. The company specializes in the development of antibody-based therapies aimed at improving patient outcomes. Below is an extensive description of the segments, products, and services offered by Innate Pharma.
Segments
1. Oncology: Innate Pharma is heavily invested in developing therapies for different cancer types, including both solid tumors (such as breast, lung, and colon cancers) and hematological malignancies (such as leukemia and lymphoma). This segment is at the forefront of the companys research and development activities, with a keen emphasis on immuno-oncology, an area that leverages and enhances the bodys immune response to target and destroy cancer cells.
2. Inflammation: In this segment, Innate Pharma focuses on treating various chronic inflammatory diseases, including autoimmune disorders and inflammatory bowel diseases. The strategies employed aim to modulate immune responses, which can help alleviate symptoms and improve the quality of life for affected patients. Targeting the underlying mechanisms of inflammation is a key aspect of the research undertaken in this segment.
Products and Services
1. Monalizumab: Monalizumab is a significant product candidate developed by Innate Pharma. It is a humanized monoclonal antibody that targets NKG2A, an inhibitory receptor present on natural killer (NK) and T cells within the tumor microenvironment. By inhibiting NKG2A, Monalizumab seeks to reactivate these immune cells and bolster the anti-tumor immune response. Clinical trials are underway to evaluate its efficacy both as a monotherapy and in combinations with other cancer treatments.
2. Lacutamab: Lacutamab is another critical candidate targeting the KIR3DL2 receptor expressed by certain cancerous cells in cutaneous T-cell lymphomas (CTCL). By selectively binding to this receptor, Lacutamab aims to deliver targeted cytotoxicity to the cancerous cells, offering a more precise therapeutic option for patients suffering from this rare type of non-Hodgkin lymphoma.
3. IPH5401: This investigational therapeutic is an antibody that targets the C5aR1 receptor, which plays a significant role in complement activation and is implicated in various immune responses. By inhibiting C5aR1, IPH5401 seeks to alter the tumor microenvironment to enhance the effectiveness of immune responses against tumors. This makes it an exciting prospect for combination therapy with other cancer immunotherapies.
4. Research Collaborations: Innate Pharma actively engages in partnerships with pharmaceutical companies, academic institutions, and research organizations to broaden its therapeutic pipeline. These collaborations allow for shared expertise, resource pooling, and the exchange of intellectual property, enabling the development of innovative treatment options and accelerating the path to market for new therapies.
5. Preclinical and Clinical Development Services: Beyond its pipeline of therapies, Innate Pharma provides a suite of development services that includes preclinical and clinical research. The companys expertise in immunology and immuno-oncology underpins its ability to support partners in designing and executing clinical trials, conducting early-stage research, and navigating regulatory landscapes. This breadth of services supports external stakeholders in advancing their own therapeutic portfolios.
Conclusion Innate Pharma SA is deeply committed to pioneering innovative treatments for cancer and inflammatory diseases. Through its extensive portfolio of product candidates, strategic collaborations, and development services, the company positions itself as a pivotal player in the biopharmaceutical landscape, driving forward the future of therapies designed to enhance patient care and outcomes. The focus on antibody-based therapies represents a significant advancement in how diseases are treated, emphasizing the importance of tailored approaches that engage the immune system effectively.
Annual Report on Innate Pharma Sa Divisions, Sales by Country
Proceeds from collaboration and licensing agreements
6.89 %
of total Revenue
of which monalizumab agreement - AstraZeneca
2.44 %
of total Revenue
of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program
4.44 %
of total Revenue
of which Takeda agreement 2023
18.5 %
of total Revenue
Others
5.56 %
of total Revenue
Twelve months ended 2025
IPHA s Annual Revenue by Geography and Business Segments
Sales (in millions $)
% (of total Sales)
Proceeds from collaboration and licensing agreements
0.69
6.89 %
of which monalizumab agreement - AstraZeneca
0.25
2.44 %
of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program
0.45
4.44 %
of which Takeda agreement 2023
1.87
18.5 %
Others
0.56
5.56 %
Total
10.09
100 %
Twelve months ended 2025
IPHA s Annual Income by Country and Business Segments
Income (in millions $)
% (Profit Margin)
Total
-55.08
-
Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments
% Y/Y Sales Growth
% Y/Y Income Growth
Proceeds from collaboration and licensing agreements
-94.1 %
-
of which monalizumab agreement - AstraZeneca
-95 %
-
of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program
-0.25 %
-
of which Takeda agreement 2023
-19.13 %
-
Others
794.64 %
-
of which Sanofi agreement 2016
-
-
of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to the option exercise
-
-
of which other agreements
-
-
Total
-55.25 %
-
of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to the progress of related research program
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
6.89 %